$ARQT News

Arcutis Biotherapeutics (NASDAQ:ARQT) Clears All Eight Growth Rules as Fundamentals Accelerate

Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026

Arcutis Biotherapeutics (NASDAQ:ARQT) Looks Undervalued as Growth and Margins Support the Value Case

Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb

Clinical Data Update Could Shape The Case For Arcutis Biotherapeutics Stock

Arcutis Soars 12% as Guggenheim Lifts Target to $44 on “Growing Conviction” in 2027

Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44

Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48

Arcutis Biotherapeutics (ARQT) Showcased Fresh ZORYVE Data, Is It Still 28% Below Fair Value?

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Arcutis Presents ZORYVE Data At EADV Congress

Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award

Arcutis Biotherapeutics: An Emerging GARP Stock

Arcutis: Every Beat Gets Absorbed By A Shrinking Multiple (Rating Downgrade)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth and Improving Fundamentals

Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options

Arcutis Biotherapeutics (NASDAQ:ARQT): Affordable Growth With Strong Upside Potential

Arcutis Biotherapeutics (NASDAQ:ARQT): Strong Growth Meets a High-Quality Technical Setup

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?